Sponsors (32)
The bill expands Medicare coverage for genetic testing, high‑risk screening, and preventive cancer surgery—improving early detection and access for high‑risk beneficiaries—while increasing federal health spending and creating implementation and administrative challenges that could cause delays or limit some repeat testing.
Medicare beneficiaries at heightened hereditary‑cancer risk gain covered access to guideline‑based germline mutation testing, guideline‑recommended high‑risk screening, and risk‑reducing cancer surgery, improving early detection and preventive care.
Clearer coverage rules tied to evidence‑based oncology guidelines should reduce prior‑authorization denials and make it easier for CMS, providers, and beneficiaries to determine when testing, screening, or preventive surgery is payable.
Aligning Medicare coverage with clinical guidelines reduces unnecessary tests and administrative denials, lowering out‑of‑pocket costs and simplifying billing for beneficiaries and providers.
Expanding Medicare coverage for genetic testing, more frequent high‑risk screening, and risk‑reducing surgery will increase Medicare spending and could put pressure on program finances, taxpayers, or other benefits.
New guideline‑based coverage rules and contractor determinations introduce administrative complexity and implementation variability for CMS, contractors, and providers, which could cause delays, appeals, or inconsistent access across regions.
The statute explicitly denies payment for repeat germline testing for the same person, which could block clinically indicated repeat tests in some cases and harm patient care.
Based on analysis of 4 sections of legislative text.
Requires Medicare to cover guideline‑based germline cancer testing, pay for recommended risk‑reducing surgery, and relax screening limits for mutation carriers (coverage at least annually).
Expands Medicare coverage to pay for germline (inherited) cancer gene testing for people with personal or family histories that suggest hereditary cancer, and treats risk‑reducing surgery recommended by evidence‑based oncology guidelines as reasonable and necessary care. It also requires Medicare to relax frequency limits on guideline‑recommended cancer screening for beneficiaries found to carry a hereditary cancer gene mutation, with coverage required at least annually. The bill ties testing and screening coverage to evidence‑based clinical practice guidelines from recognized oncology organizations and directs Medicare contractors to use the least restrictive guideline when guidelines conflict. The changes apply to services furnished on or after enactment.
Official title: To amend title XVIII of the Social Security Act to provide hereditary cancer genetic testing for individuals with a history of a hereditary cancer gene mutation in a blood relative or a personal or ancestral history suspicious for hereditary cancer, and to provide coverage of certain cancer screenings or preventive surgeries that would reduce the risk for individuals with a germline (inherited) mutation associated with a high risk of developing a preventable cancer.
Introduced July 23, 2025 by Debbie Wasserman Schultz · Last progress July 23, 2025